Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting

Blood Adv. 2019 Apr 9;3(7):1027-1032. doi: 10.1182/bloodadvances.2018027227.

Abstract

  1. Teriflunomide, the active metabolite of leflunomide, downregulates c-Myc expression through inhibition of PIM kinases.

  2. Leflunomide together with lenalidomide significantly extended survival in an in vivo MM model.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Drug Synergism
  • Drug Therapy, Combination / methods
  • Enzyme Inhibitors / therapeutic use
  • Humans
  • Leflunomide / therapeutic use*
  • Lenalidomide / therapeutic use
  • Mice
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / metabolism
  • Proto-Oncogene Proteins c-myc / metabolism*
  • Proto-Oncogene Proteins c-pim-1 / antagonists & inhibitors*
  • Tumor Cells, Cultured

Substances

  • Enzyme Inhibitors
  • Proto-Oncogene Proteins c-myc
  • Proto-Oncogene Proteins c-pim-1
  • Lenalidomide
  • Leflunomide